1
|
Bordin DS, Voynovan IN, Sarsenbaeva AS, Zaytsev OV, Abdulkhakov RA, Bakulina NV, Bakulin IG, Osipenko MF, Livzan MA, Alekseenko SA, Tarasova LV, Tarasova GN, Bogomolov PO, Maev IV, Andreev DN, Abdulkhakov SR, Starostin BD, Bakanova NV, Kononova AG, Kolbasnikov SV, Bueverova EL, Moreira L, Megraud F, O'Morain C, Perez Nyssen O, Gisbert J. [Effectiveness of empirical Helicobacter pylori eradication therapy with furazolidone in Russia: results from the European Registry on Helicobacter pylori Management (Hp-EuReg)]. TERAPEVT ARKH 2023; 95:120-129. [PMID: 37167127 DOI: 10.26442/00403660.2023.02.202107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Accepted: 03/29/2023] [Indexed: 05/13/2023]
Abstract
BACKGROUND First-line therapy does not always provide a high level of Helicobacter pylori eradication due to the increase of H. pylori resistance to antibiotics; therefore, it remains necessary to identify the most effective rescue treatments. The purpose of this study was to evaluate the efficacy and safety of empirical H. pylori furazolidone-containing regimens. MATERIALS AND METHODS Adult H. pylori infected patients empirically treated with furazolidone-containing eradication regimens were registered in an international, prospective, multicenter non-intervention European registry on H. pylori management (Hp-EuReg). Data were collected at AEG-REDCap e-CRF from 2013 to 2021 and the quality was reviewed. Modified intention-to-treat (mITT) effectiveness analyses were performed. RESULTS Overall 106 patients received empirical furazolidone-containing therapy in Russia. Furazolidone was prescribed in a sequential scheme along with amoxicillin, clarithromycin and a proton pump inhibitor in 68 (64%) cases, triple regimens were prescribed in 28 (26%) patients and quadruple regimens in 10 (9.4%). Treatment duration of 7 days was assigned to 2 (1.9%) patients, 10-day eradication therapy in case of 80 (75%) and 14 days - in 24 (23%) patients. Furazolidone was mainly used in first- (79%) and second-line (21%) regimens. The methods used to diagnose H. pylori infection were: histology (81%), stool antigen test (64%), 13C-urea breath test (6.6%), and rapid urease test (1.9%). The mITT effectiveness of sequential therapy was 100%; 93% with the triple therapy and 75.5% with quadruple therapy. Compliance was reported in 98% of cases. Adverse events were revealed in 5.7% of patients, mostly nausea (3.8%). No serious adverse events were reported. CONCLUSION Furazolidone containing eradication regimens appear to be an effective and safe empirical therapy in Russia.
Collapse
Affiliation(s)
- D S Bordin
- Loginov Moscow Clinical Scientific Center
- Yevdokimov Moscow State University of Medicine and Dentistry
- Tver State Medical University
| | | | | | | | | | - N V Bakulina
- Mechnikov North-Western State Medical University
| | - I G Bakulin
- Mechnikov North-Western State Medical University
| | | | | | | | | | | | - P O Bogomolov
- Yevdokimov Moscow State University of Medicine and Dentistry
- Private Medical Center "Universal"
- Vladimirsky Moscow Regional Clinical Research Institute
| | - I V Maev
- Yevdokimov Moscow State University of Medicine and Dentistry
| | - D N Andreev
- Yevdokimov Moscow State University of Medicine and Dentistry
| | | | | | | | | | | | - E L Bueverova
- Sechenov First Moscow State Medical University (Sechenov University)
| | - L Moreira
- Hospital Clínic de Barcelona
- Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd)
- University of Barcelona
| | | | | | - O Perez Nyssen
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
- Universidad Autónoma de Madrid (UAM)
| | - J Gisbert
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)
- Universidad Autónoma de Madrid (UAM)
| |
Collapse
|
2
|
Ivashkin VT, Lapina TL, Maev IV, Drapkina OM, Kozlov RS, Sheptulin AA, Trukhmanov AS, Abdulkhakov SR, Alekseeva OP, Alekseenko SA, Andreev DN, Bordin DS, Dekhnich NN, Klyaritskaya IL, Korochanskaya NV, Osipenko MF, Poluektova EA, Sarsenbaeva AS, Simanenkov VI, Tkachev AV, Ulyanin AI, Khlynov IB, Tsukanov VV. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for <i>H. pylori</i> Diagnostics and Treatment in Adults. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022; 32:72-93. [DOI: 10.22416/1382-4376-2022-32-6-72-93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/20/2023]
Abstract
Aim: bring to the attention of practitioners indications for anti-Helicobacter therapy, methods and procedure for diagnostics and eradication therapy of Н. pylori infection.Key points. Chronic gastritis caused by Н. pylori infection, including asymptomatic persons, may be considered as an indication for eradication therapy of Н. pylori as etiological therapy and opportunistic screening for gastric cancer prevention. Indications, for obligatory anti-Helicobacter therapy include peptic ulcer, gastric MALT lymphoma, early gastric cancer (EGC) with endoscopic resection. H. pylori primary diagnostics methods include 13C-urea breath test, H. pylori stool antigen lab test, rapid urease test and serological method. The serological method cannot be used after anti-Helicobacter therapy.In Russia H. pylori strains' resistance to clarithromycin does not exceed 15 % in most regional studies. The first line therapy for Н. pylori infection eradication is the standard triple therapy including a proton pump inhibitor (PPI), clarithromycin and amoxicillin, enhanced with bismuthate tripotassium dicitrate. A classic four-component therapy based on bismuthate tripotassium dicitrate or quadrotherapy without bismuth drug products which includes PPI, amoxicillin, clarithromycin and metronidazole, may be used as alternative to the first line eradication therapy. The standard triple therapy may be prescribed for 14 days only in those regions, where it has been proven to be effective. Quadrotherapy with bismuthate tripotassium dicitrate is also used as main second line therapy in case of standard triple therapy, bismuth enhanced standard triple therapy or combined therapy failure. Another second line therapy includes PPI, levofloxacin and amoxicillin, to which a bismuth-containing drug product may be added. The third line therapy is selected individually based on previously used treatment settings.Conclusion. In each case of H. pylori infection the decision for eradication therapy should be made, which is especially relevant as eradication of H. pylori has been recognized as an effective measure for the prevention of gastric cancer.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - D. S. Bordin
- Endocrinology Research Centre; Loginov Moscow Clinical Scientific Center; Tver State Medical University
| | | | | | | | | | | | | | | | | | | | | | - V. V. Tsukanov
- Research Institute for Medical Problems in the North - Division of Krasnoyarsk Scientific Centre of Siberian Branch of the RAS
| |
Collapse
|
3
|
Ivashkin VT, Lapina TL, Maev IV, Drapkina OM, Kozlov RS, Sheptulin AA, Trukhmanov AS, Abdulkhakov SR, Alekseeva OP, Alekseenko SA, Andreev DN, Bordin DS, Dekhnich NN, Klyaritskaya IL, Korochanskaya NV, Osipenko MF, Poluektova EA, Sarsenbaeva AS, Simanenkov VI, Tkachev AV, Ulyanin AI, Khlynov IB, Tsukanov VV. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for <i>H. pylori</i> Diagnostics and Treatment in Adults. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022; 32:72-93. [DOI: https:/doi.org/10.22416/1382-4376-2022-32-6-72-93] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Abstract
Aim: bring to the attention of practitioners indications for anti-Helicobacter therapy, methods and procedure for diagnostics and eradication therapy of Н. pylori infection.Key points. Chronic gastritis caused by Н. pylori infection, including asymptomatic persons, may be considered as an indication for eradication therapy of Н. pylori as etiological therapy and opportunistic screening for gastric cancer prevention. Indications, for obligatory anti-Helicobacter therapy include peptic ulcer, gastric MALT lymphoma, early gastric cancer (EGC) with endoscopic resection. H. pylori primary diagnostics methods include 13C-urea breath test, H. pylori stool antigen lab test, rapid urease test and serological method. The serological method cannot be used after anti-Helicobacter therapy.In Russia H. pylori strains' resistance to clarithromycin does not exceed 15 % in most regional studies. The first line therapy for Н. pylori infection eradication is the standard triple therapy including a proton pump inhibitor (PPI), clarithromycin and amoxicillin, enhanced with bismuthate tripotassium dicitrate. A classic four-component therapy based on bismuthate tripotassium dicitrate or quadrotherapy without bismuth drug products which includes PPI, amoxicillin, clarithromycin and metronidazole, may be used as alternative to the first line eradication therapy. The standard triple therapy may be prescribed for 14 days only in those regions, where it has been proven to be effective. Quadrotherapy with bismuthate tripotassium dicitrate is also used as main second line therapy in case of standard triple therapy, bismuth enhanced standard triple therapy or combined therapy failure. Another second line therapy includes PPI, levofloxacin and amoxicillin, to which a bismuth-containing drug product may be added. The third line therapy is selected individually based on previously used treatment settings.Conclusion. In each case of H. pylori infection the decision for eradication therapy should be made, which is especially relevant as eradication of H. pylori has been recognized as an effective measure for the prevention of gastric cancer.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - D. S. Bordin
- Endocrinology Research Centre; Loginov Moscow Clinical Scientific Center; Tver State Medical University
| | | | | | | | | | | | | | | | | | | | | | - V. V. Tsukanov
- Research Institute for Medical Problems in the North - Division of Krasnoyarsk Scientific Centre of Siberian Branch of the RAS
| |
Collapse
|
4
|
Simanenkov VI, Alekseenko SA. [Prospects for personalized Helicobacter pylori eradication therapy. Pro et contra]. TERAPEVT ARKH 2022; 94:935-939. [PMID: 36286973 DOI: 10.26442/00403660.2022.08.201787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Indexed: 06/16/2023]
Abstract
The article is devoted to debatable aspects of Helicobacter pylori eradication therapy. The eradication cancer-preventive effects are considered. A negative comorbidity between H. pylori infection and such diseases as gastroesophageal reflux disease, inflammatory bowel disease and bronchial asthma has been described. The perspectives of populational, individualized and personalized strategies for H. pylori eradication therapy assessment are given. Recommendations for individualized H. pylori eradication strategy implementation in practical healthcare are proposed.
Collapse
|
5
|
Ivashkin VT, Maev IV, Abdulganieva DI, Alekseenko SA, Gorelov AV, Zakharova IN, Zolnikova OY, Ivashkina NY, Korochanskaya NV, Mammayev SN, Poluektova EA, Trukhmanov AS, Usenko DV, Uspensky YP, Tsukanov VV, Shifrin OS, Berezhnaya IV, Ivashkin KV, Lapina TL, Maslennikov RV, Nikolaeva SV, Sugyan NG, Ulyanin AI. Practical Recommendations of Scientific Society for the Study of Human Microbiome and the Russian Gastroenterological Association on Use of Probiotics, Prebiotics, Synbiotics and Functional Foods in Treatment and Prevention of Gastroenterological Diseases in Children and Adults. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2021. [DOI: 10.22416/1382-4376-2021-31-2-65-91] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Aim. The practical guidelines are intended for primary care physicians, general practitioners, paediatricians, gastroenterologists and general internists to advance the treatment and prevention of gastroenterological diseases in adults and children in therapies with probiotics, prebiotics, synbiotics and their enriched functional foods.Key points. Probiotics are live microorganisms that sustain health of the host when supplied in adequate amounts. Prebiotics include human-indigestible but accessible to gut microbiota substances expediting specific changes in the composition and/or activity of gastrointestinal microbiota that favour the host health. The mechanism of probiotic action comprises the quorum resistance maintenance, nutrient substrate metabolism and end metabolite recycling, macroorganism-sustaining substrate production, as well as the mediation of local and adaptive immune responses.The Russian Federation regulates market differently for biologically active food additives (BAFA), medicinal products (drugs) and functional food products (FFP). We overview the probiotic strains regulated in Russia as BAFAs, drugs and FFPs and provide recommendations on the use of these strains in treatment and prevention of gastroenterological diseases in children and adults.Conclusion. The clinical efficacy of probiotics, prebiotics, synbiotics and fortified functional foods depends on the prebiotic and strain properties and is verified in appropriate comparative clinical trials. Not all probiotics registered in Russia as BAFAs, drugs and FFPs have a strain identity, which provides no warranty of the clinical effect expected. The FFP legislation demands improved regulation mechanisms and control for therapeutic efficacy.
Collapse
Affiliation(s)
- V. T. Ivashkin
- Sechenov First Moscow State University (Sechenov University)
| | - I. V. Maev
- Yevdokimov Moscow State University of Medicine and Dentistry
| | | | | | - A. V. Gorelov
- Sechenov First Moscow State University (Sechenov University); Central Research Institute of Epidemiology
| | - I. N. Zakharova
- Russian Medical Academy of Continuous Professional Education
| | | | | | | | | | | | | | - D. V. Usenko
- Russian Medical Academy of Continuous Professional Education
| | | | - V. V. Tsukanov
- Research Institute for Medical Problems in the North — Division of Krasnoyarsk Scientific Centre of the Siberian Branch of the RAS
| | - O. S. Shifrin
- Sechenov First Moscow State University (Sechenov University)
| | | | - K. V. Ivashkin
- Sechenov First Moscow State University (Sechenov University)
| | - T. L. Lapina
- Sechenov First Moscow State University (Sechenov University)
| | | | | | - N. G. Sugyan
- Russian Medical Academy of Continuous Professional Education
| | - A. I. Ulyanin
- Sechenov First Moscow State University (Sechenov University)
| |
Collapse
|
6
|
Lazebnik LB, Golovanova EV, Alekseenko SA, Bueverov AO, Plotnikova EY, Dolgushina AI, Ilchenko LY, Ermolova TV, Tarasova LV, Lee ED, Tsyganova YV, Akhmedov VA, Ageeva EA, Losev VM, Kupriyanova IN, Serikova SN, Korochanskaya NV, Vologzhanina LG, Zimmerman YS, Sas EI, Zhuravel SV, Okovitiy SV, Osipenko MF, Radchenko VG, Soldatova GS, Sitkin SI, Seliverstov PV, Shavkuta GV, Butova EN, Kozhevnikova SA. Russian Consensus “Hyperammonemia in Adults” (Version 2021). jour 2021:97-118. [DOI: 10.31146/1682-8658-ecg-187-3-97-118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/26/2023]
Abstract
Justification Given the large number of reports on the peculiarities of liver lesions during the Sars-Cov-2 infection [1], a team of experts who participated in the 23rd Congress of the Scientific Society of Gastroenterologists of Russia and 15 National Congress of Therapists of November 19, 2020 decided to make additions to the Russian Consensus of “Hyperammonemia in Adults” published early 2020 [2, 3].
Collapse
Affiliation(s)
- L. B. Lazebnik
- “Moscow State University of Medicine and Density n. a. A. I. Evdokimov”
| | - E. V. Golovanova
- “Moscow State University of Medicine and Density n. a. A. I. Evdokimov”
| | | | - A. O. Bueverov
- I. M. Sechenov first Moscow state medical university (Sechenov university); Moscow regional research and clinical Institute of M. F. Vladimirsky
| | - E. Yu. Plotnikova
- Federal State Budgetary Institution of Higher Education Kemerovo state medical University of the Ministry of health of Russia
| | - A. I. Dolgushina
- “South-Ural State Medical University” of the Ministry of Health of Russia
| | - L. Yu. Ilchenko
- Pirogov Russian National Research Medical University (RNRMU)
| | - T. V. Ermolova
- North- Western state medical University named after I. I. Mechnikov, Ministry of health of the Russian Federation
| | - L. V. Tarasova
- BI of HE “The Surgut State University”; “The Chuvashian State University”
| | - E. D. Lee
- Multifocal Medicine Center of The Central Bank of Russian Federation
| | | | - V. A. Akhmedov
- “Omsk State Medical University” of the Ministry of Health
| | | | | | - I. N. Kupriyanova
- “Ural state medical University” of the Ministry of health of the Russian Federation
| | - S. N. Serikova
- State Budgetary Institution of Health Care “Region Clinic Hospital Nr 2” Health Ministry of Krasnodar Region
| | - N. V. Korochanskaya
- State Budgetary Institution of Health Care “Region Clinic Hospital Nr 2” Health Ministry of Krasnodar Region
| | - L. G. Vologzhanina
- “Perm State Medical University named E. A. Wagner” of the Ministry of Health of Russia
| | - Ya. S. Zimmerman
- “Perm State Medical University named E. A. Wagner” of the Ministry of Health of Russia
| | - E. I. Sas
- Military Medical Academy named after S. M. Kirov
| | - S. V. Zhuravel
- “Moscow State University of Medicine and Density n. a. A. I. Evdokimov”; Scientific Research Institute of Emergency Medicine of N. V. Sklifosovskiy of Healthcare Department of Moscow
| | - S. V. Okovitiy
- Saint Petersburg State Chemical Pharmaceutical University (SPCPA)
| | - M. F. Osipenko
- Public budgetary educational institution of higher education “Novosibirsk State Medical University” of the Ministry of Healthcare of the Russia
| | | | | | - S. I. Sitkin
- North- Western state medical University named after I. I. Mechnikov, Ministry of health of the Russian Federation; Federal Medical and Biological Agency “State Research Institute of Highly Pure Biopreparations”
| | - P. V. Seliverstov
- North- Western state medical University named after I. I. Mechnikov, Ministry of health of the Russian Federation
| | - G. V. Shavkuta
- Rostov State Medical University of the Ministry of Health of Russia
| | - E. N. Butova
- Rostov State Medical University of the Ministry of Health of Russia
| | | |
Collapse
|
7
|
Lazebnik LB, Golovanova EV, Turkina SV, Raikhelson KL, Okovityy SV, Drapkina OM, Maev IV, Martynov AI, Roitberg GE, Khlynova OV, Abdulganieva DI, Alekseenko SA, Ardatskaya MD, Bakulin IG, Bakulina NV, Bueverov AO, Vinitskaya EV, Volynets GV, Eremina EY, Grinevich VB, Dolgushina AI, Kazyulin AN, Kashkina EI, Kozlova IV, Konev YV, Korochanskaya NV, Kravchuk YA, Li ED, Loranskaya ID, Makhov VM, Mekhtiev SN, Novikova VP, Ostroumova OD, Pavlov CS, Radchenko VG, Samsonov AA, Sarsenbaeva AS, Sayfutdinov RG, Seliverstov PV, Sitkin SI, Stefanyuk OV, Tarasova LV, Tkachenko EI, Uspensky YP, Fominykh YA, Khavkin AI, Tsyganova YV, Sharhun OO. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. jour 2021; 1:4-52. [DOI: 10.31146/1682-8658-ecg-185-1-4-52] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/26/2023]
Affiliation(s)
- L. B. Lazebnik
- Federal State Budgetary Educational Institution of Higher Education “A. I. Yevdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russion Federation
| | - E. V. Golovanova
- Federal State Budgetary Educational Institution of Higher Education “A. I. Yevdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russion Federation
| | - S. V. Turkina
- State-funded Educational Establishment of Higher Professional Education «Volgograd State Medical University of the Ministry of Public Health of the Russian Federation»
| | | | - S. V. Okovityy
- Saint Petersburg State Chemical Pharmaceutical University (SPCPA)
| | - O. M. Drapkina
- National Medical Research Center for Therapy and Preventive Medicine of the Russian Ministry of Health
| | - I. V. Maev
- Federal State Budgetary Educational Institution of Higher Education “A. I. Yevdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russion Federation
| | - A. I. Martynov
- Federal State Budgetary Educational Institution of Higher Education “A. I. Yevdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russion Federation
| | - G. E. Roitberg
- Pirogov Russian National Research Medical University; JSC «Medicine»
| | - O. V. Khlynova
- Perm State Medical University named after academician E. A. Vagner Ministry of Health care of Russia
| | | | | | - M. D. Ardatskaya
- Federal State Budgetary Institution “Central Clinical Hospital”, of the Russian Federation Presidential Administration
| | - I. G. Bakulin
- North- Western state medical University named after I. I. Mechnikov, Ministry of health of the Russian Federation
| | - N. V. Bakulina
- North- Western state medical University named after I. I. Mechnikov, Ministry of health of the Russian Federation
| | - A. O. Bueverov
- Moscow regional research and clinical Institute of M. F. Vladimirsky
| | | | | | | | | | | | - A. N. Kazyulin
- Federal State Budgetary Educational Institution of Higher Education “A. I. Yevdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russion Federation
| | | | - I. V. Kozlova
- Saratov State Medical University n. a. V. I. Razumovsky
| | - Yu. V. Konev
- Federal State Budgetary Educational Institution of Higher Education “A. I. Yevdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russion Federation
| | - N. V. Korochanskaya
- Federal State Budgetary Educational Institution of Higher Education Kuban State Medical University Health Ministry of Russian Federation
| | | | - E. D. Li
- Multifunctional medical center of the Bank of Russia
| | - I. D. Loranskaya
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of the Ministry of Healthcare of the Russian Federation
| | - V. M. Makhov
- I. M. Sechenov First Moscow Medical State University
| | - S. N. Mekhtiev
- Institute of Professional Retraining of the International Medical Center “SOGAZ”
| | | | - O. D. Ostroumova
- Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of the Ministry of Healthcare of the Russian Federation
| | - Ch. S. Pavlov
- I. M. Sechenov First Moscow Medical State University
| | | | - A. A. Samsonov
- Federal State Budgetary Educational Institution of Higher Education “A. I. Yevdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russion Federation
| | | | - R. G. Sayfutdinov
- Kazan State Medical Academy — Branch Campus of the Federal State Budgetary Educational Institution of Further Professional Education “Russian Medical Academy of Continuous Professional Education” of the Ministry of Healthcare of the Russian Federation, central scientifi c research laboratory
| | - P. V. Seliverstov
- North-Western state medical University named after I. I. Mechnikov, Ministry of health of the Russian Federation
| | - S. I. Sitkin
- North-Western state medical University named after I. I. Mechnikov, Ministry of health of the Russian Federation
| | - O. V. Stefanyuk
- Federal State Budgetary Educational Institution of Higher Education “A. I. Yevdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russion Federation; National Medical Research Center for Therapy and Preventive Medicine of the Russian Ministry of Health
| | | | | | | | | | - A. I. Khavkin
- Pirogov Russian National Research Medical University
| | | | - O. O. Sharhun
- Pirogov Russian National Research Medical University
| |
Collapse
|
8
|
Simanenkov VI, Maev IV, Tkacheva ON, Alekseenko SA, Andreev DN, Bordin DS, Vlasov TD, Vorobyeva NM, Grinevich V, Gubonina IV, Drobizhev MY, Efremov NS, Karateev АE, Kotovskaya YV, Kravchuk IA, Krivoborodov GG, Kulchavenya EV, Lila AM, Mayevskaya MV, Poluektova EA, Popkova TV, Sablin OA, Solovyeva OI, Suvorov AN, Tarasova GN, Trukhan DI, Fedotova AV. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovasc Ther Prev 2021. [DOI: 10.15829/1728-8800-2021-2758] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Affiliation(s)
- V. I. Simanenkov
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - I. V. Maev
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - O. N. Tkacheva
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - S. A. Alekseenko
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - D. N. Andreev
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - D. S. Bordin
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - T. D. Vlasov
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - N. M. Vorobyeva
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - V. Grinevich
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - I. V. Gubonina
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - M. Yu. Drobizhev
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - N. S. Efremov
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - А. E. Karateev
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - Yu. V. Kotovskaya
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - Iu. A. Kravchuk
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - G. G. Krivoborodov
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - E. V. Kulchavenya
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - A. M. Lila
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - M. V. Mayevskaya
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - E. A. Poluektova
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - T. V. Popkova
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - O. A. Sablin
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - O. I. Solovyeva
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - A. N. Suvorov
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - G. N. Tarasova
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - D. I. Trukhan
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| | - A. V. Fedotova
- National Medical Association for the Study of the Multimorbidity; Fund PROFMEDFORUM
| |
Collapse
|
9
|
Ivashkin VT, Mayev IV, Abdulganieva DI, Alekseenko SA, Ivashkina NY, Korochanskaya NV, Mammaev SN, Poluektova EA, Trukhmanov AS, Uspensky YP, Tsukanov VV, Shifrin OS, Zolnikova OY, Ivashkin KV, Lapina TL, Maslennikov RV, Ulyanin AI. Practical Recommendations of Scientific Society for the Study of Human Microbiome and Russian Gastroenterological Association (RGA) for Probiotics in Treatment and Prevention of Gastroenterological Diseases in Adults. ACTA ACUST UNITED AC 2020. [DOI: 10.22416/1382-4376-2020-30-2-76-89] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Aim. To provide practical recommendations on the use of probiotics for the treatment and prevention of gastroenterological diseases in adults.General provisions. Probiotics are living microorganisms that benefit the health of the host when administered in adequate amounts. The main functions of probiotics include the support for colonisation resistance, the metabolism of food substrates and utilisation of end metabolites, the production of substrates necessary for the macro-organism, as well as the regulation of local and adaptive immune responses. Probiotics can be registered in the Russian Federation as biologically active food additives (BAFA) or as pharmaceutical products (drugs) in accordance with the microbiological standards and legislative requirements of the Russian Federation. The probiotics registered in the Russian Federation as BAFA for adults include bacteria of the Lactobacillus, Bifidobacterium, Enterococcus, Pediococcus, Lactococcus, Streptococcus, Bacillus, and Escherichia genera, and fungi of the Saccharomyces genus; probiotics registered as drugs — bacteria of Lactobid, Lactobacid, Escherichia and Enterococcus genera and fungi of the Saccharomyces genus. Some probiotics registered in the Russian Federation include probiotic strains that have proved to be effective for the prevention and treatment of antibiotic-associated diarrhea, the prevention of C. difficile-associated disease, the eradication of H. pylori infection, as well as for the treatment of irritable bowel syndrome and functional constipation.Conclusions. The clinical efficacy of probiotics depends on the probiotic strains included in their composition and is confirmed by a comparative analysis of the results of appropriate clinical studies. Not all probiotics registered in the Russian Federation as BAFA or drugs contain bacterial or fungal strains; as a result, the expected clinical effect may not be achieved.
Collapse
Affiliation(s)
- V. T. Ivashkin
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - I. V. Mayev
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry
| | | | | | - N. Yu. Ivashkina
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry
| | | | | | - E. A. Poluektova
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - A. S. Trukhmanov
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | | | - V. V. Tsukanov
- Federal Research Centre “Krasnoyarsk Scientific Centre of the Siberian Branch of the Russian Academy of Sciences” — Scientific Research Institute of Medical Problems of the North
| | - O. S. Shifrin
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - O. Yu. Zolnikova
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - K. V. Ivashkin
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - T. L. Lapina
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - R. V. Maslennikov
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| | - A. I. Ulyanin
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
| |
Collapse
|
10
|
Bordin DS, Embutnieks YV, Vologzhanina LG, Il'chishina TA, Voinovan IN, Sarsenbaeva AS, Alekseenko SA, Zaitsev OV, Abdulkhakov RA, Osipenko MF, Livzan MA, Tsukanov VV, Burkov SG, Bakulina NV, Dekhnich NN, Tarasova LV, Plotnikova EY, Maev IV, Kucheryavyi YA, Baryshnikova NV, Butov MA, Kolbasnikov SV, Pakhomova AL, Zhestkova TV, Baranovskii AY, Abdulkhakov SR, Ageeva EA, Lyalyukova EA, Vasyutin AV, Golubev NN, Savilova IV, Morkovkina LV, Kononova AG, Megraud F, O'Morain C, Ramas M, Nyssen OP, McNicholl AG, Gisbert JP. European Registry on the management of Helicobacter pylori infection (Hp-EuReg): analysis of 2360 patients receiving first-line therapy in Russia. TERAPEVT ARKH 2019; 90:35-42. [PMID: 30701770 DOI: 10.26442/terarkh201890235-42] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
AIM European Registry on the management of Helicobacter pylori infection («Hp-EuReg») - a multicenter prospective observational study initiated by the European Helicobacter and Microbiota Study Group, conducted in 27 European countries in order to evaluate the real clinical practice of diagnosis and treatment of H. pylori and its comparison with international recommendations. MATERIALS AND METHODS The analysis of 2360 patients entered in the register by the Russian centres of «Hp-EuReg» in 2013-2017, who were underwent 1st line eradication therapy. RESULTS The most common methods of primary diagnosis of H. pylori are histological (37.7%), rapid urease test (29.2%) and serology (29.7%). The duration of eradication therapy in 9.4% of cases was 7 days, in 65.3% - 10 days, and in 25.3% - 14 days. To control the effec- tiveness of treatment, H. pylori antigen in feces (31.3%), urea breath test (23.4%) and histological method (23.3%) were used. In 3.6% cases was used serology by mistake. In 17.3% of patients control was not carried out. The effectiveness of triple therapy with a PPI, amoxicillin, clar- ithromycin (per protocol) was 67.6%, with 7-day course, 81.1% at 10-day and 86.7% at 14-day course. Eradication rate of triple therapy with addition of bismuth (per protocol) reached 90,6% in the group receiving 10-day scheme and 93.6% in the group receiving the 14-day treatment. CONCLUSION Significant deviations of clinical practice from expert recommendations, most pronounced at the stage of monitoring the effectiveness of therapy, were noted. The suboptimal efficacy of triple therapy is shown.
Collapse
Affiliation(s)
- D S Bordin
- A.S. Loginov Moscow clinical scientific practical center of Moscow Healthcare Department , Moscow, Russia.,Tver state medical University, Ministry of health of Russia, Tver, Russia
| | - Yu V Embutnieks
- A.S. Loginov Moscow clinical scientific practical center of Moscow Healthcare Department , Moscow, Russia
| | | | | | - I N Voinovan
- A.S. Loginov Moscow clinical scientific practical center of Moscow Healthcare Department , Moscow, Russia
| | - A S Sarsenbaeva
- South Ural state medical University, Ministry of Health of Russia, Chelyabinsk, Russia
| | - S A Alekseenko
- Far Eastern State Medical University, Ministry of Health of Russia, Khabarovsk, Russia
| | - O V Zaitsev
- The First clinical medical center, Kovrov, Russia
| | - R A Abdulkhakov
- Kazan state medical University, Ministry of Health of Russia, Kazan, Russia
| | - M F Osipenko
- Novosibirsk state medical University, Ministry of Health of Russia, Novosibirsk, Russia
| | - M A Livzan
- Omsk state medical University, Ministry of health of Russia, Omsk, Russia
| | - V V Tsukanov
- Krasnoyarsk scientific center of the Siberian branch of the Russian Academy of Sciences, separat of division "Scientific research Institute of medical problems of the North", Krasnoyarsk, Russia
| | - S G Burkov
- Polyclinic №3 of Department for presidential Affairs of the Russian Federation, Moscow, Russia
| | - N V Bakulina
- I.I. Mechnikov North-Western state medical University, Ministry health of Russia, St. Petersburg, Russia
| | - N N Dekhnich
- Smolensk state medical University Ministry of health of Russia, Smolensk, Russia
| | - L V Tarasova
- Republican gastroenterology center, "Republican clinical hospital", Ministry of health of Chuvash Republic, I.N. Ulyanov state University, Cheboksary, Russia
| | - E Yu Plotnikova
- Kemerovo state medical University, Ministry health of Russia, Kemerovo, Russia
| | - I V Maev
- A.I. Evdokimov Moscow state medical dental University, Ministry of Health of Russia, Moscow, Russi
| | - Yu A Kucheryavyi
- A.I. Evdokimov Moscow state medical dental University, Ministry of Health of Russia, Moscow, Russi
| | - N V Baryshnikova
- Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia, St. Petersburg, Russia
| | - M A Butov
- I.P. Pavlov Ryazan State Medical University, Ministry of health of Russia, Ryazan, Russia
| | - S V Kolbasnikov
- Tver state medical University, Ministry of health of Russia, Tver, Russia
| | - A L Pakhomova
- V. I. Razumovsky Saratov state medical University, Ministry of health of Russia, Saratov, Russia
| | - T V Zhestkova
- I.P. Pavlov Ryazan State Medical University, Ministry of health of Russia, Ryazan, Russi
| | | | - S R Abdulkhakov
- Kazan state medical University, Ministry of Health of Russia, Kazan, Russia.,Kazan (Volga region) Federal University, Kazan, Russia
| | - E A Ageeva
- Far Eastern State Medical University, Ministry of Health of Russia, Khabarovsk, Russia
| | - E A Lyalyukova
- Omsk state medical University, Ministry of health of Russia, Omsk, Russia
| | - A V Vasyutin
- Krasnoyarsk scientific center of the Siberian branch of the Russian Academy of Sciences, separat of division "Scientific research Institute of medical problems of the North", Krasnoyarsk, Russia
| | - N N Golubev
- Polyclinic №3 of Department for presidential Affairs of the Russian Federation, Moscow, Russia
| | - I V Savilova
- I.I. Mechnikov North-Western state medical University, Ministry health of Russia, St. Petersburg, Russia
| | - L V Morkovkina
- Republican gastroenterology center, "Republican clinical hospital", Ministry of health of Chuvash Republic, I.N. Ulyanov state University, Cheboksary, Russia
| | - A G Kononova
- Tver state medical University, Ministry of health of Russia, Tver, Russia
| | - F Megraud
- Laboratoire of Bacteriology, Hospital Pellegrin, Bordeaux, France
| | - C O'Morain
- Department of Gastroenterology, Tallaght Hospital/Trinity College Dublin, Dublin, Ireland
| | - M Ramas
- Gastroenterology Unit, University Hospital «Princess», the Institute of Research in Health "Princess" (IIS-IP), Biomedical Research Centre Network of Hepatic and Digestive Diseases (CIBERehd), and Autonomous University of Madrid (UAM), Madrid, Spain
| | - O P Nyssen
- Gastroenterology Unit, University Hospital «Princess», the Institute of Research in Health "Princess" (IIS-IP), Biomedical Research Centre Network of Hepatic and Digestive Diseases (CIBERehd), and Autonomous University of Madrid (UAM), Madrid, Spain
| | - A G McNicholl
- Gastroenterology Unit, University Hospital «Princess», the Institute of Research in Health "Princess" (IIS-IP), Biomedical Research Centre Network of Hepatic and Digestive Diseases (CIBERehd), and Autonomous University of Madrid (UAM), Madrid, Spain
| | - J P Gisbert
- Gastroenterology Unit, University Hospital «Princess», the Institute of Research in Health "Princess" (IIS-IP), Biomedical Research Centre Network of Hepatic and Digestive Diseases (CIBERehd), and Autonomous University of Madrid (UAM), Madrid, Spain
| |
Collapse
|
11
|
Khatkov IE, Maev IV, Abdulkhakov SR, Alekseenko SA, Alikhanov RB, Bakulin IG, Bakulina NV, Baranovskiy AY, Beloborodova EV, Belousova EA, Voskanyan SE, Vinokurova LV, Grinevich VB, Darvin VV, Dubtsova EA, Dyuzheva TG, Egorov VI, Efanov MG, Izrailov RE, Korobka VL, Kotiv BN, Kokhanenko NY, Kucheryavyy YA, Livzan MA, Lyadov VK, Nikolskaya KA, Osipenko MF, Pasechnikov VD, Plotnikova EY, Sablin OA, Simanenkov VI, Tsvirkun VV, Tsukanov VV, Shabunin AV, Bordin DS. Russian consensus on exo- and endocrine pancreatic insufficiency after surgical treatment. TERAPEVT ARKH 2019; 90:13-26. [PMID: 30701935 DOI: 10.26442/terarkh201890813-26] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The Russian consensus on exo- and endocrine pancreatic insufficiency after surgical treatment was prepared on the initiative of the Russian "Pancreatic Club" on the Delphi method. His goal was to clarify and consolidate the opinions of specialists on the most relevant issues of diagnosis and treatment of exo- and endocrine insufficiency after surgical interventions on the pancreas. An interdisciplinary approach is provided by the participation of leading gastroenterologists and surgeons.
Collapse
Affiliation(s)
- I E Khatkov
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia.,A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
| | - I V Maev
- A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
| | - S R Abdulkhakov
- Kazan State Medical University, Ministry of Health of Russia, Kazan, Russia
| | - S A Alekseenko
- The Far Eastern State Medical University, Ministry of Health of Russia, Khabarovsk, Russia
| | - R B Alikhanov
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - I G Bakulin
- I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint-Petersburg, Russia
| | - N V Bakulina
- I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint-Petersburg, Russia
| | | | - E V Beloborodova
- Siberian State Medical University, Ministry of Health of Russia, Tomsk, Russia
| | - E A Belousova
- M.F. Vladimirskiy Moscow Regional Research and Clinical Institute, Moscow, Russia
| | - S E Voskanyan
- A.I. Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russia
| | - L V Vinokurova
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - V B Grinevich
- S.M. Kirov Military Medical Academy, Ministry of Defence of Russia, Saint-Petersburg, Russia
| | - V V Darvin
- Medical Institute of Surgut State University, Surgut, Russia
| | - E A Dubtsova
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - T G Dyuzheva
- I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia, Moscow, Russia
| | - V I Egorov
- City Clinical Hospital named after the Bakhrushin Brothers, Moscow, Russia
| | - M G Efanov
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - R E Izrailov
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - V L Korobka
- Rostov State Medical University, Ministry of Health of Russia, Rostov-on-Don, Russia
| | - B N Kotiv
- S.M. Kirov Military Medical Academy, Ministry of Defence of Russia, Saint-Petersburg, Russia
| | - N Yu Kokhanenko
- Saint-Petersburg State Pediatric Medical University, Ministry of Health of Russia, Saint-Petersburg, Russia
| | - Yu A Kucheryavyy
- A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
| | - M A Livzan
- Omsk State Medical University, Ministry of Health of Russia, Omsk, Russia
| | - V K Lyadov
- Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia, Moscow, Russia
| | - K A Nikolskaya
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - M F Osipenko
- Novosibirsk State Medical University, Ministry of Health of Russia, Novosibirsk, Russia
| | - V D Pasechnikov
- Stavropol State Medical University, Ministry of Health of Russia, Stavropol, Russia
| | - E Yu Plotnikova
- Kemerovo State Medical University, Ministry of Health of Russia, Kemerovo, Russia
| | - O A Sablin
- A.M. Nikiforov All-Russian Center for Emergency and Radiation Medicine, Russian Ministry for Emergency Situations, Saint-Petersburg, Russia
| | - V I Simanenkov
- I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint-Petersburg, Russia
| | - V V Tsvirkun
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia
| | - V V Tsukanov
- Krasnoyarsk Scientific Center of Siberian Branch in Russian Academy of Sciences, Krasnoyarsk, Russia
| | - A V Shabunin
- S.P. Botkin City Hospital, Moscow Healthcare Department, Moscow, Russia
| | - D S Bordin
- A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia.,Tver State Medical University, Ministry of Health of Russia, Tver, Russia
| |
Collapse
|
12
|
Bordin DS, Embutnieks YV, Vologzhanina LG, Ilchishina TA, Voynovan IN, Sarsenbaeva AS, Zaitsev OV, Alekseenko SA, Abdulkhakov RA, Dehnich NN, Osipenko MF, Livzan MA, Tsukanov VV, Burkov SG, Bakulina NV, Plotnikova EY, Tarasova LV, Maev IV, Kucheryavyi YA, Baryshnikova NV, Butov MA, Kolbasnikov SV, Pakhomova AL, Zhestkova TV, Baranovsky AY, Abdulhakov SR, Ageeva EA, Lyalyukova EA, Vasyutin AV, Golubev NN, Savilova IV, Morkovkina LV, Kononova AG, Megraud F, O'Morain C, Ramas M, Nyssen OP, McNicholl AG, Gisbert JP. [European registry Helicobacter pylori (Hp-EuReg): how has clinical practice changed in Russia from 2013 to 2018 years]. TERAPEVT ARKH 2019; 91:16-24. [PMID: 32598623 DOI: 10.26442/00403660.2019.02.000156] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Indexed: 12/25/2022]
Abstract
The multicenter prospective observational study initiated by the European Helicobacter and Microbiota Study Group (EHMSG) is conducted in 27 countries in Europe. The data from the Russian part of the European registry for the management of Helicobacter pylori infection (European Registry on the management of Helicobacter pylori infection, protocol: "Hp-EuReg") allows us to analyze the real clinical practice of diagnosis and treatment of H. pylori and compare it with international recommendations. MATERIALS AND METHODS A comparative analysis of the data entered in the register by the Russian research centers "Hp-EuReg", in the period from 2013 to 2018, was conducted. RESULTS AND DISCUSSION Invasive diagnostic methods prevail for the primary diagnosis of H. pylori [histology - 20.3% (in 2013 year) - 43.9% (in 2018 year), rapid urease test - 31.7% and 47.8% respectively]. The most popular mode of eradication therapy is a 10-day triple therapy (62.8-76.2%), the effectiveness of which does not exceed 79% (per protocol). Invasive tests (histology) are the leading method for control the effectiveness of therapy, however, there is a tendency towards a wider use of non-invasive methods (H. pylori stool antigen - from 17% in 2013 to 29.3% in 2018 and urea breath test from 6.9 to 18.3%, respectively). Serological test to control the effectiveness of eradication is still used from 8.2% (2013) to 6.1% (2018). Eradication therapy was not performed in 28% of patients throughout the entire observation period. CONCLUSION In Russia, despite approved domestic and international recommendations, deviations in clinical practice persist, both during eradication therapy and in monitoring the effectiveness of eradication therapy.
Collapse
Affiliation(s)
- D S Bordin
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow
| | - Y V Embutnieks
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow
| | | | | | - I N Voynovan
- A.S. Loginov Moscow Clinical Research and Practical Center of the Department of Health of Moscow
| | - A S Sarsenbaeva
- South Ural State Medical University of the Ministry of Health of the Russian Federation
| | | | - S A Alekseenko
- Far-Eastern State Medical University of the Ministry of Health of the Russian Federation
| | - R A Abdulkhakov
- Kazan State Medical University of the Ministry of Health of the Russian Federation
| | - N N Dehnich
- Smolensk State Medical University of the Ministry of Health of the Russian Federation
| | - M F Osipenko
- Novosibirsk State Medical University of the Ministry of Health of the Russian Federation
| | - M A Livzan
- Omsk State Medical University of the Ministry of Health of the Russian Federation
| | - V V Tsukanov
- Research Institute for Medical Problems of the North
| | - S G Burkov
- Polyclinic № 3 of the Department for Presidential Affairs of the Russian Federation
| | - N V Bakulina
- I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation
| | - E Y Plotnikova
- Kemerovo State Medical Academy of the Ministry of Health of the Russian Federation
| | - L V Tarasova
- Republican Gastroenterology Center, Republican Clinical Hospital of the Ministry of Health and Social Development of Chuvashia.,I.N. Ulyanov Chuvash State University
| | - I V Maev
- A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
| | - Y A Kucheryavyi
- A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
| | - N V Baryshnikova
- I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation
| | - M A Butov
- I.P. Pavlov Ryazan State Medical University of the Ministry of Health of the Russian Federation
| | - S V Kolbasnikov
- Tver State Medical University of the Ministry of Health of the Russian Federation
| | | | - T V Zhestkova
- I.P. Pavlov Ryazan State Medical University of the Ministry of Health of the Russian Federation
| | | | - S R Abdulhakov
- Kazan State Medical University of the Ministry of Health of the Russian Federation.,Kazan Federal University
| | - E A Ageeva
- Municipal outpatient clinic №3, Ministry of Health of Khabarovsk Region
| | - E A Lyalyukova
- Omsk State Medical University of the Ministry of Health of the Russian Federation
| | - A V Vasyutin
- Research Institute for Medical Problems of the North
| | - N N Golubev
- Polyclinic № 3 of the Department for Presidential Affairs of the Russian Federation
| | - I V Savilova
- I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation
| | - L V Morkovkina
- Republican Gastroenterology Center, Republican Clinical Hospital of the Ministry of Health and Social Development of Chuvashia
| | - A G Kononova
- Tver State Medical University of the Ministry of Health of the Russian Federation
| | - F Megraud
- Laboratoire de Bactériologie, Hôpital Pellegrin
| | - C O'Morain
- Department of Gastroenterology, Tallaght Hospital/Trinity College Dublin
| | - M Ramas
- Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Universidad Autónoma de Madrid (UAM)
| | - O P Nyssen
- Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Universidad Autónoma de Madrid (UAM)
| | - A G McNicholl
- Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Universidad Autónoma de Madrid (UAM)
| | - J P Gisbert
- Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), and Universidad Autónoma de Madrid (UAM)
| |
Collapse
|
13
|
Khatkov IE, Maev IV, Bordin DS, Kucheryavyi YA, Abdulkhakov SR, Alekseenko SA, Alieva EI, Alikhanov RB, Bakulin IG, Baranovsky AY, Beloborodova EV, Belousova EA, Buriev IM, Bystrovskaya EV, Vertyankin SV, Vinokurova LV, Galperin EI, Gorelov AV, Grinevich VB, Danilov MV, Darvin VV, Dubtsova EA, Dyuzheva TG, Egorov VI, Efanov MG, Zakharova NV, Zagainov VE, Ivashkin VT, Izrailov RE, Korochanskaya NV, Kornienko EA, Korobka VL, Kokhanenko NY, Livzan MA, Loranskaya ID, Nikolskaya KA, Osipenko MF, Okhlobystin AV, Pasechnikov VD, Plotnikova EY, Polyakova SI, Sablin OA, Simanenkov VI, Ursova NI, Tsvirkun VV, Tsukanov VV, Shabunin AV. The Russian consensus on the diagnosis and treatment of chronic pancreatitis: Enzyme replacement therapy. TERAPEVT ARKH 2017; 89:80-87. [PMID: 28914856 DOI: 10.17116/terarkh201789880-87] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023]
Abstract
Pancreatology Club Professional Medical Community, 1A.S. Loginov Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow; 2A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow; 3Kazan State Medical University, Ministry of Health of Russia, Kazan; 4Kazan (Volga) Federal University, Kazan; 5Far Eastern State Medical University, Ministry of Health of Russia, Khabarovsk; 6Morozov City Children’s Clinical Hospital, Moscow Healthcare Department, Moscow; 7I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg; 8Siberian State Medical University, Ministry of Health of Russia, Tomsk; 9M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow; 10Maimonides State Classical Academy, Moscow; 11V.I. Razumovsky State Medical University, Ministry of Health of Russia, Saratov; 12I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow; 13S.M. Kirov Military Medical Academy, Ministry of Defense of Russia, Saint Petersburg; 14Surgut State Medical University, Ministry of Health of Russia, Surgut; 15City Clinical Hospital Five, Moscow Healthcare Department, Moscow; 16Nizhny Novgorod Medical Academy, Ministry of Health of Russia, Nizhny Novgorod; 17Territorial Clinical Hospital Two, Ministry of Health of the Krasnodar Territory, Krasnodar; 18Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia, Saint Petersburg; 19Rostov State Medical University, Ministry of Health of Russia, Rostov-on-Don; 20Omsk Medical University, Ministry of Health of Russia, Omsk; 21Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, Moscow; 22Novosibirsk State Medical University, Ministry of Health of Russia, Novosibirsk; 23Stavropol State Medical University, Ministry of Health of Russia, Stavropol; 24Kemerovo State Medical University, Ministry of Health of Russia, Kemerovo; 25N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow; 26A.M. Nikiforov All-Russian Center of Emergency and Radiation Medicine, Russian Ministry for Civil Defense, Emergencies and Elimination of Consequences of Natural Disasters, Saint Petersburg; 27Research Institute for Medical Problems of the North, Siberian Branch, Russian Academy of Sciences, Krasnoyarsk; 28S.P. Botkin City Clinical Hospital, Moscow Healthcare Department, Moscow; 29Tver State Medical University, Ministry of Health of Russia, Tver The Russian consensus on the diagnosis and treatment of chronic pancreatitis has been prepared on the initiative of the Russian Pancreatology Club to clarify and consolidate the opinions of Russian specialists (gastroenterologists, surgeons, and pediatricians) on the most significant problems of diagnosis and treatment of chronic pancreatitis. This article continues a series of publications explaining the most significant interdisciplinary consensus statements and deals with enzyme replacement therapy.
Collapse
|
14
|
Khatkov IE, Maev IV, Abdulkhakov SR, Alekseenko SA, Alieva EI, Alikhanov RB, Bakulin IG, Baranovsky AY, Beloborodova EV, Belousova EA, Buriev IM, Bystrovskaya EV, Vertyankin SV, Vinokurova LV, Galperin EI, Gorelov AV, Grinevich VB, Danilov MV, Darvin VV, Dubtsova EA, Dyuzheva TG, Egorov VI, Efanov MG, Zakharova NV, Zagainov VE, Ivashkin VT, Izrailov RE, Korochanskaya NV, Kornienko EA, Korobka VL, Kokhanenko NY, Kucheryavyi YA, Livzan MA, Loranskaya ID, Nikolskaya KA, Osipenko MF, Okhlobystin AV, Pasechnikov VD, Plotnikova EY, Polyakova SI, Sablin OA, Simanenkov VI, Ursova NI, Tsvirkun VV, Tsukanov VV, Shabunin AV, Bordin DS. The Russian consensus on the diagnosis and treatment of chronic pancreatitis. TERAPEVT ARKH 2017; 89:105-113. [DOI: 10.17116/terarkh2017892105-113] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/20/2023]
Abstract
1Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow; 2A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow; 3Kazan State Medical University, Kazan; 4Kazan (Volga) Federal University, Kazan; 5Far Eastern State Medical University, Ministry of Health of Russia, Khabarovsk; 6Morozov City Children’s Clinical Hospital, Moscow Healthcare Department, Moscow; 7I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg; 8Siberian State Medical University, Ministry of Health of Russia, Tomsk; 9M.F. Vladimirsky Moscow Regional Research Clinical Institute, Moscow; 10Maimonides State Classical Academy, Moscow; 11V.I. Razumovsky Saratov State Medical University, Saratov; 12I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow; 13S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg; 14Surgut State Medical University, Ministry of Health of Russia, Surgut; 15City Clinical Hospital Five, Moscow Healthcare Department, Moscow; 16Nizhny Novgorod Medical Academy, Ministry of Health of Russia, Nizhny Novgorod; 17Territorial Clinical Hospital Two, Ministry of Health of the Krasnodar Territory, Krasnodar; 18Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia, Saint Petersburg; 19Rostov State Medical University, Ministry of Health of Russia, Rostov-on-Don; 20Omsk Medical University, Ministry of Health of Russia, Omsk; 21Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia, Moscow; 22Novosibirsk State Medical University, Novosibirsk; 23Stavropol State Medical University, Ministry of Health of Russia, Stavropol; 24Kemerovo State Medical University, Ministry of Health of Russia, Kemerovo; 25N.I. Pirogov Russian Research Medical University, Ministry of Health of Russia, Moscow; 26A.M. Nikiforov All-Russian Center of Emergency and Radiation Medicine, Ministry of Emergency Situations of Russia, Saint Petersburg; 27Federal Research Center, Krasnoyarsk Research Center, Siberian Branch, Russian Academy of Sciences, Research Institute of Medical Problems of the North, Krasnoyarsk; 28S.P. Botkin City Clinical Hospital, Moscow Healthcare Department, Moscow; 29Tver State Medical University, Ministry of Health of Russia, Tver The Russian consensus (a consensus document) on the diagnosis and treatment of chronic pancreatitis has been prepared on the initiative of the Russian «Pancreatic Club» under the Delphi system. Its aim was to identify and consolidate the opinions of Russian experts on the most topical issues of the diagnosis and treatment of chronic pancreatitis. The interdisciplinary approach involved the participation of leading gastroenterologists, surgeons, and pediatricians.
Collapse
|
15
|
Ostapenko Y, Puchkov YB, Shchupak AY, Alekseenko SA, Lebed'ko OA, Brusin KM, Sentsov VG, Novikova OV, Zobnin YV, Vishnevetskiy MK. Author's response to: ‘Causality between polyhexamethyleneguanidine occurrence in unrecorded alcohol and cholestatic hepatitis outbreak in Russia’. Clin Toxicol (Phila) 2012. [DOI: 10.3109/15563650.2011.646356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
16
|
Ostapenko YN, Brusin KM, Zobnin YV, Shchupak AY, Vishnevetskiy MK, Sentsov VG, Novikova OV, Alekseenko SA, Lebed'ko OA, Puchkov YB. Acute cholestatic liver injury caused by polyhexamethyleneguanidine hydrochloride admixed to ethyl alcohol. Clin Toxicol (Phila) 2011; 49:471-7. [PMID: 21761961 DOI: 10.3109/15563650.2011.592837] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
INTRODUCTION Polyhexamethyleneguanidine hydrochloride (PHMG) is an antimicrobial biocide of the guanidine family. In the period from August 2006 to May 2007, more than 12500 patients were admitted to hospital with a history of drinking illegal cheap "vodka" in 44 different regions in Russia, of whom 9.4% died. In reality, the "vodka" was an antiseptic liquid composed of ethanol (≈93%), diethyl phthalate, and 0.1-0.14% PHMG (brand name "Extrasept-1"). MATERIAL AND METHODS We performed an analysis of the clinical features and outcome in four poisoning treatment centers in the cities of Perm, Ekaterinburg, Irkutsk, and Khabarovsk. A total of 579 patients (215 females and 364 males) with similar symptoms were included. RESULTS The main symptoms on admission included jaundice (99.7%), skin itch (78.4%), weakness (96%), anorexia (65.8%), dizziness (65.3%), nausea (54.8%), vomiting (22.6%), stomach ache (52.7%), diarrhea (32%), and fever (50%). Mild symptoms were found in 2.5% of cases, moderate in 63%, and severe in 34.5%. Laboratory results were (mean ± SD): total bilirubin 249 ± 158 μmol/L, direct bilirubin 166 ± 97 μmol/L, cholesterol 14 ± 8 mmol/L, alanine aminotransferase 207 ± 174 IU/L, aspartate aminotransferase 174 ± 230 IU/L, alkaline phosphatase 742 ± 751 IU/L, and gamma-glutamyltranspeptidase 1199 ± 1095 IU/L. Patients generally recovered over a period of 1-5 months, although high levels of alkaline phosphatase and gamma-glutamyltranspeptidase were still found in all patients examined after 6 months. Sixty-one patients (10.5%) died between 23 and 150 days after poisoning. Local cholestasis, inflammatory infiltration, and fibrosis developing into cirrhosis were found by liver biopsy. CONCLUSION Acute liver injury caused by PHMG-hydrochloride or PHMG in combination with either ethanol or diethyl phthalate can be characterized as cholestatic hepatitis with a severe inflammatory component causing high mortality.
Collapse
Affiliation(s)
- Y N Ostapenko
- Research and Applied Toxicology Center of the Federal Medical-Biological Agency, Moscow, Russia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Svetlov SA, Spiridonov FF, Alekseenko SA. Modeling of the liquid flow in the upstream portion of a cylindrical channel. Theor Found Chem Eng 2005. [DOI: 10.1007/pl00022161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
18
|
Svetlov SA, Spiridonov FF, Alekseenko SA. Modeling of the liquid flow in the upstream portion of a cylindrical channel. Theor Found Chem Eng 2005. [DOI: 10.1007/s11236-005-0008-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Alekseenko SA, Timoshin SS, Avilova AA, Fleĭshman MI, Lamekhova VG. [Effect of enalapril, lisinopril, and amlodipine on the course of chronic gastrititis in patients with arterial hypertension]. Klin Med (Mosk) 2004; 82:42-5. [PMID: 15540422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
A hundred and thirty-six patients with mild and moderate arterial hypertension (AH) who had received angiotensin-converting enzyme inhibitors (ACEIs) (enalapril and lisinopril) and the calcium channel blocker amlodipine were examined. The use of the above ACEIs promoted the normalization of proliferative processes in the epithelium of the gastric mucosa (GM) in patients with AH and concomitant chronic gastritis. This effect ofACEIs is not related to an antihypertensive effect since the antihypertensive agent amlodipine fails to exert such an effect on GM. The revealed fact of the positive effect ofACEIs not only on the morphological characteristics of GM, but also on the severity of the dyspeptic syndrome is important from the clinical point of view.
Collapse
|
20
|
Nikonov EL, Alekseenko SA, Fedchenko VI, Gur'ev SO, Konekava EG. [Ways to optimize therapy of acid-dependent diseases]. Eksp Klin Gastroenterol 2003:18-20, 181. [PMID: 12664777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
The range of antisecretory preparations used by a gastroenterologist now includes a new reliable preparation. Nexium, which allows solving the problem of optimization of treatment of patients with acid-dependent diseases.
Collapse
Affiliation(s)
- E L Nikonov
- State Medical University of the Far East, Khabarovsk Scientific Research Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences, Moscow
| | | | | | | | | |
Collapse
|
21
|
Alekseenko SA, Krapivnaia OV, Kamalova OK, Vasiaev VI, Pyrkh AV. [Dynamics of clinical symptoms, indices of quality of life, and the state of motor function of the esophagus and rectum in patients with functional dyspepsia and irritable bowel syndrome after Helicobacter pylori eradication]. Eksp Klin Gastroenterol 2003:54-8, 115. [PMID: 14653240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
94 patients with irritable bowel syndrome and functional dyspepsia were included in the study. To confirm the diagnosis of H. pylori infection, all patients underwent fibroesophagogastroduodenoscopy with histological and urea tests before and 5 weeks after treatment. Standard eradication was performed. 25 patients underwent intraesophageal and anorectal manometry using the Polygraf device, Sweden. The dynamics of clinical symptoms, life quality (SF-36), manometry data and data of the histological examination of the stomach mucous coat was assessed. 63.5% of patients had clinical improvements following the eradication. The threshold of rectal sensitivity rose in 40% of patients. The esophageal motor function normalized in 48% of patients. An improvement of the morphological picture of chronic gastritis was recorded in 58.7% of patients.
Collapse
Affiliation(s)
- S A Alekseenko
- State Medical University of the Far East, Road Clinical Hospital of the Khabarovsk-I Station, Khabarovsk
| | | | | | | | | |
Collapse
|
22
|
Alekseenko SA, Timoshin SS. [The effect of histamine H2 receptor blockers on reparative processes in the gastric mucosa of patients with gastric peptic ulcer]. TERAPEVT ARKH 1999; 71:23-6. [PMID: 10222548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
AIM To investigate effects of histamine H2-receptor antagonists (cimetidine, famotidine) on proliferative activity of gastric mucosa of patients with acute gastric ulcer. MATERIALS AND METHODS We treated 74 patients (54 men and 20 women) with acute benign mediogastric ulcer at the age of 28-56 years. Group 1 consisted of 24 patients who received antacid; group 2--of 26 patients on 1 g/day cimetidine; group 3--24 patients who received famotidine 40 mg qPM. We assessed clinical efficiency of three-week therapy, grade of ulcer healing, proliferative activity of antral and fundic gastric epithelium and ulcer margin epithelium using autoradiography with 3H-thymidine. RESULTS Clinical efficiency of histamine H2-receptor antagonists was significantly higher than of antacid. Cimetidine and famotidine stimulate proliferative activity in the epithelium of ulcer margins. CONCLUSION The ability to stimulate proliferative activity of gastric mucosa makes H2-receptor antagonists an effective modality in acute gastric ulcer with low acid secretion.
Collapse
|
23
|
Alekseenko SA, Timoshin SS. [Effects of histamine H2-receptor blockers and dalargin on reparative processes gastroduodenal mucosa in patients with duodenal ulcer]. Klin Med (Mosk) 1996; 74:52-4. [PMID: 9121092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The effect of synthetic opiate peptide dalargin, histamine H2-receptors blockers (cimetidin, famotidin) and combination of dalargin with famotidin on proliferative activity of gastroduodenal mucosal epithelium has been studied autoradiographically (3H-thymidine) in 75 patients with duodenal ulcer. Compared to spasmolytics and antacids, the studied drugs (dalargin, cimetidin and famotidin) significantly increased the number of DNA-synthetizing cells in the epithelium of fundal stomach, duodenal cap and ulcer borders. Maximal effect was noticed in combined use of dalargin and famotidin. A correlation existed between clinical and stimulating reparative effect of the drugs.
Collapse
Affiliation(s)
- S A Alekseenko
- Department of Hospital Therapy, State Medical Institute, Khabarovsk
| | | |
Collapse
|
24
|
Timoshin SS, Alekseenko SA, Shtuka AA. [Effect of dalargin on repair capacity of gastroduodenal mucosa in patients with duodenal ulcer]. Klin Med (Mosk) 1991; 69:75-7. [PMID: 2067344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Changes in the number of DNA-synthesizing nuclei of gastroduodenal mucosa in duodenal ulcer were monitored for patients treated with dalargin versus standard therapy (spasmolytics and antacids). In contrast to the standard treatment, dalargin 20-day administration produced a significant increase in the index of 3H-thymidine-labelled epithelial nuclei in fundal and duodenal bulb mucosa. The capacity for activating DNA synthesis in gastroduodenal mucosa may represent an essential mechanism of dalargin therapeutic action.
Collapse
|
25
|
Geller LI, Alekseenko SA. [Disorders of the gastric mucosal barrier for the reverse diffusion of hydrogen ions as a clinical problem]. Klin Med (Mosk) 1984; 62:25-31. [PMID: 6381876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
26
|
Geller LI, Alekseenko SA, Bessonova GA. [Clinical significance of the electrolyte barrier and the regenerative capacity of the gastric mucosa]. Vrach Delo 1981:23-6. [PMID: 6977238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
27
|
Geller LI, Alekseenko SA. [Rate of regeneration of the gastroduodenal mucosa epithelium in chronic gastritis and peptic ulcer]. Klin Med (Mosk) 1981; 59:71-6. [PMID: 7289532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
28
|
Simon NB, Timoshin SS, Alekseenko SA. Changes in mitotic activity of the corneal epithelium of albino rats cooled at different times of day. Bull Exp Biol Med 1976. [DOI: 10.1007/bf00790396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|